Scientists at the Gladstone Institutes have determined how specific circuitry in the brain controls not only body movement but also motivation and learning, providing new insight into neurodegenerative disorders such as Parkinson's disease—and psychiatric disorders such as addiction and depression.
Scientists at the Gladstone Institutes have unraveled a process by which depletion of a specific protein in the brain contributes to the memory problems associated with Alzheimer's disease. These findings provide insights into the disease's development and may lead to new therapies that could benefit the millions of people worldwide suffering from Alzheimer's and other devastating neurological disorders.
The Robert J. and Claire Pasarow Foundation will next week present Gladstone Institutes Senior Investigator and President Emeritus Robert W. Mahley, MD, PhD, with its 2012 Award in Cardiovascular Research, bestowing yet another honor upon Gladstone's founding scientist.
Scientists at the Gladstone Institutes have enhanced our understanding of how a protein linked to Alzheimer's disease keeps young brains healthy, but can damage them later in life—suggesting new research avenues for treating this devastating disease.
Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance—the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.
Scientists at the Gladstone Institutes, an independent and nonprofit biomedical-research organization, have identified a protein that exacerbates symptoms of Parkinson's disease—a discovery that could one day lead to new treatments for people who suffer from this devastating neurodegenerative illness.
Bristol-Myers Squibb Company (NYSE:BMY) and the Gladstone Institutes today announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.
ddddSAN FRANCISCO, CA—November 15, 2011—The American Heart Association will today present Gladstone Institutes Senior Investigator and President Emeritus Robert Mahley, MD, PhD, with the 2011 AHA Distinguished Scientist Award, bestowing yet another honor on one of Gladstone’s founding cardiovascular scientists.
Gladstone Institutes Assistant Investigator Anatol Kreitzer, PhD, has won the prestigious 2011 Young Investigator Award from the Society for Neuroscience. Dr. Kreitzer, who is also an assistant professor of physiology and neurology at the University of California, San Francisco (UCSF), will share the award with UCSF Associate Professor of Physiology Loren Frank, PhD.
Scientists at the Gladstone Institutes have identified a protein that kick–starts the response to low levels of oxygen, suggesting new lines of research relevant to a variety of potentially fatal disorders associated with diminished oxygen supply, including cancer, heart disease, stroke and other neurological conditions that affect millions of people worldwide.